{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"description":"Presence of active/aberrant kinase pathways will be determined using a small molecule kinase inhibitor screen, to rapidly identify therapeutic tyrosine kinase targets in leukemia patients while simultaneously providing individualized therapeutic options. Will be correlated with treatment response, mutational analysis using next generation sequencing, and characterization of aberrant gene expression in primary leukemia samples.","groups":[{"description":"Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nDasatinib: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies","id":"OG000","title":"Group I (Dasatinib)"},{"description":"Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nSunitinib: Given PO\n\nSunitinib Malate: Given PO","id":"OG001","title":"Group II (Sutinib Malate)"},{"description":"Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nSorafenib: Given PO\n\nSorafenib Tosylate: Given PO","id":"OG002","title":"Group III (Sorafenib Tosylate)"},{"description":"Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nPonatinib: Given PO\n\nPonatinib Hydrochloride: Given PO","id":"OG003","title":"Group IV (Ponatinib Hydrochloride)"},{"description":"Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPacritinib: Given PO\n\nPharmacological Study: Correlative studies","id":"OG004","title":"Group V (Pacritinib)"},{"description":"Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nRuxolitinib: Given PO","id":"OG005","title":"Group VI (Ruxolitinib)"},{"description":"Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nIdelalisib: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies","id":"OG006","title":"Group VII (Idelalisib)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Presence of Active/Aberrant Kinase Pathways","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}